Ultevursen

Usher syndrome, a rare genetic disorder causing hearing and vision loss, lacks a cure. DelveInsight's report forecasts market growth at a 10.55% CAGR by 2034, highlighting key companies and emerging therapies. The US leads in prevalent cases, with treatments focusing on managing symptoms and ongoing research for potential therapies.

The Usher syndrome market is projected to grow at a CAGR of 10.55% by 2034, reaching USD 76.48 million in 2023 across 7MM. Leading companies are developing novel therapies, with the US having the highest prevalent cases. No cure exists, but management includes hearing aids, cochlear implants, and low vision aids. Research aims to improve quality of life for those affected.

The Usher Syndrome market, valued at USD 77 million in 2023 across 7MM, is expected to grow through 2034. Key therapies include Ultevursen, NPI-001, and AAV-USH1C, with companies like Laboratoires Théa and Nacuity Pharmaceuticals leading innovations. AAVantgarde Bio's AAVB-081 received FDA Orphan Drug Designation. The market's growth is driven by new therapies and gene-based research, addressing the genetic disorder's hearing loss and retinopathy.

The Usher syndrome market is poised for significant growth due to emerging therapies in clinical trials by key players like LABORATOIRES THÉA and NACUITY PHARMACEUTICALS. With a 2023 market size of USD 76.48 million across 7MM, advancements in gene therapy and treatments like ULTEVURSEN and NPI-001 are expected to drive market expansion, despite challenges like treatment costs and access.

Usher Syndrome (USH), a leading cause of deaf-blindness, lacks a cure, with treatments focusing on managing symptoms. The US leads in prevalence, with 21,000 cases in 2023. Market size was ~USD 77 million, expected to grow. Luxturna is the only approved therapy for retinal degeneration. Emerging treatments like NPI-001 and Ultevursen are in trials, aiming to address the disease's root cause.

The Usher syndrome market, valued at US$ 1.2 Billion in 2023, is projected to grow to US$ 1.7 Billion by 2034, with a CAGR of 3.61%. This rare genetic disorder, causing hearing and progressive vision loss, is driven by gene mutations and advancements in therapeutic solutions like cochlear and retinal implants. The market benefits from rehabilitation techniques, R&D for novel treatments, and gene therapy. The US leads in patient pool and market size. Recent developments include ProQR Therapeutics' asset divestiture. Key treatments under development include NT-501 and Ultevursen, targeting vision loss in Usher syndrome.